R&D

Achievement

2017

  • Immuno-oncologyBispecific Antibody

    Innovent

    • Collaboration to develop and market Immuno-oncology Bispecific Antibody

2016

  • Treatment and prevention of influenza virus infectionHANMI FLU®Capsule & Suspension powder

    HANMI FLU

    • Oseltamivir freebase Formulation
    • Suspension powder allows accurate dose administration and taste improvement for pediatric patients
    • Economical health insurance drug price
  • The first-line therapy for BPHHanmitams 0.4mg capsule

    Hanmitams 0.4mg capsule

    • Korea’s first tamsulosin HCl 0.4mg
  • Once daily BPH+ED combination drugGugutams capsule

    Gugutams capsule

    • Korea's first urological combination drug of tamsulosin and tadalafil
    • Improve voiding symptoms and erectile dysfunction in patients with benign prostate hyperplasia and erectile dysfunction
    • Polycap formulation allows different release patterns for each ingredient and
    • minimizes drug-drug interaction between each ingredient
  • HM95573

    genentech

    • Licensed out RAF Inhibitor ‘HM95573’ to Genentech for Worldwide except Korea

2015

  • ROSUZET®tab.

    ROSUZET

    • Combination drug of Rosuvastatin + Ezetimibe
    • Phase 3 results were published in the nternational science journals(Cardiovascular Therapeutics) (2016)
    • Export contract with MSD to 23 countries(2017)
  • Olmutinib

    zailab

    • Licensed out EGFR Mutant Selective Inhibitor ‘Olmutinib’ to ZAI Lab for People's Republic of China including Hong Kong and Macau
  • HM12525A

    janssen

    • Licensed out Long-acting GLP-1/Glucagon Receptor Dual Agonist 'HM12525A' to Janssen for Worldwide except Korea and People's Republic of China
  • Quantum Project

    SANOFI

    • Licensed out Long-acting Diabetes Program 'Quantum Project' to Sanofi for Worldwide w/ option to co-commercialize in Korea and People's Republic of China
  • HM71224

    Eli lilly

    • Licensed out BTK Inhibitor ‘HM71224’ to Eli lilly for Worldwide except Korea, Taiwan and People's Republic of China including Hong Kong
  • Poziotinib

    Spectrum pharmaceuticals logo

    • Licensed out Pan-HER Inhibitor ‘Poziotinib’ to Spectrum Pharmaceuticals for Worldwide except Korea and People's Republic of China
    • Co-development with National OncoVenture (Government-funded)
  • ALG-1001

    Allegro license

    • Strategic investment in Allegro in US (20 mil USD)
    • Collaboration to develop and market retina therapy LUMINATE®

2014

  • Poziotinib

    Ceremony pictures

    • Licensed out Pan-HER Inhibitor ‘Poziotinib’ to Luye Pharma for People's Republic of China excluding Hong Kong and Macau
    • Co-development with National OncoVenture (Government-funded)
  • Asthma treatment inhaler possible to check drug useFluterol®Injalation Capsule

    Fluterol®Injalation Capsule

    • Self-developed inhalation asthma and COPD drug

2013

  • The world's first new IMD salt EsomeprazoleEsomezol®Capsule

    Esomezol®Capsule

    • The nation’s first FDA-approved & launched IMD product in US (2013)
    • Export to 7 countries in Southeast Asia through DKSH (2013)
  • A new combination drug for hypertension/ hyperlipidemiaRovelito®tab.

    Ceremony pictures

    • The first ARB+Statin fixed dose combination drug
    • The nation’s first joint co-development and sales with Sanofi-Aventis Korea
  • 12 hours continuous effectCossac®-L tab.

    Cossac®엘tab.

    • The nation’s first levocetirizine + pseudoephedrine isomeric complexes
  • Anti-inflammatory drug for gastroenteric disorder, reduced CV risk Naxozol®tab.

    Naxozol®tab.

    • A new combination drug in NSAIDs + PPI class
  • An active form of fenofibric acid, can be taken with or without foodFenocid®Capsule

    Fenocid®Capsule

    • Improved generic version to reduce triglyceride levels

2012

  • LAPS-GCSF

    Ceremony pictures

    • Long-acting GCSF based on LAPSCOVERY™ technology
    • Co-development & commercialization agreement with Spectrum for Worldwide except Korea, People's Republic of China and Japan
    • Plan to initiate global phase 3 study in 2015

2011

  • Oraxol/Oratecan

    Ceremony pictures

    • Licensed out Oral Discovery platform technology 'ORASCOVERY‘ to Athenex (KINEX) Pharmaceuticals for Worldwide except Korea and Japan

2009

  • The world's first amlodipine + losartan combination drugAmosartan®tab.

    Amosartan®tab.

    • The world's first hypertension combination drug in CCB + ARB class
    • Co-marketed with MSD under the trademark ‘Cozaar XQ’ over 60 countries

2008

  • Stabilized new salt form of clopidogrelPidogul®tab.

    Pidogul®tab.

    • The world's first new salt IMD of clopidogrel
    • Clinical result was published in international journal (Clinical Therapeutics, 2013)
    • Received marketing authorization from 8 European countries (2011)

2004

  • New salt form of amlodipineAmodipin®tab.

    Amodipin®tab.

    • The world's first new salt IMD of amlodipine
    • Awarded Excellent Korean Technology (KT mark) (Ministry of Science and Technology, Korea industrial technology promotion association, 2005)
    • Awarded IR52 Jang Young Shil Prize (2005)
    • Awarded Chung Mu Gong Prize (Korean Intellectual Property Office, 2003)

1997

  • Microemulsion technology of Cyclosporin A
    • Technology transfer of the novel microemulsion technology (Norvartis, 1997)

1989

  • New synthetic process of Ceftriaxone

    Ceftriaxone Inj.

    • The nation's first technology transfer (Roche, 1998)
    • The nation's first EU-GMP acquisition

1985

  • 3rd gen. cephalosporin antibiotic, Cefotaxime

    Cefotaxime

    • The nation's first Cefotaxime API development (1985)
    • The nation's first approval in China (1992)